Cetuximab-induced hypomagnesemia in patients with colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 2, 2006, Pages 152-156

  Fakih, Marwan G ^a   Wilding, Gregory ^a   Lombardo, Jeffrey ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Hypocalcemia; Magnesium

Indexed keywords

CETUXIMAB; IRINOTECAN; MAGNESIUM; MAGNESIUM SULFATE; OXALIPLATIN; POTASSIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; RISK ASSESSMENT; SKIN TOXICITY;

EID: 33749034712     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.033     Document Type: Article

References (13)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
2. Engstrom PF, Benson AB III, Chen YJ, et al. Colon cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005; 3:468-491.
3. Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97:1221-1224.
4. Berlin J, Neubauer P, Swanson, WG, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr). J Clin Oncol 2006; 24(18 suppl):158s (Abstract #3548).
5. Erbitux® [package insert]. New York, NY: ImClone Systems, Incorporated; 2006.
6. Bashir H, Crom D, Metzger M, et al. Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. Pediatr Blood Cancer 2006 [Epub ahead of print].
7. Ceremuzynski L, Gebalska J, Wolk R, et al. Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. J Intern Med 2000; 247:78-86.
8. al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1995; 24:737-752.
9. Leicher CR, Mezoff AG, Hyams JS. Focal cerebral deficits in severe hypomagnesemia. Pediatr Neurol 1991; 7:380-381.
10. Torralbo A, Portoles J, Perez Perez AJ, et al. Hypomagnesemic hypocalcemia in chronic renal failure. Am J Kidney Dis 1993; 21:167-171.
11. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 2006; 24(18 suppl):155s (Abstract #3537).
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
13. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24:394-400.